BioNTech SE (NASDAQ:BNTX) Receives $285.93 Consensus PT from Analysts

Shares of BioNTech SE (NASDAQ:BNTX) have been assigned an average rating of “Buy” from the sixteen ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $276.36.

BNTX has been the topic of a number of recent analyst reports. UBS Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating in a research report on Wednesday, December 22nd. Jefferies Financial Group set a $230.00 price target on shares of BioNTech in a research report on Wednesday, December 8th. Bank of America boosted their price target on shares of BioNTech from $341.00 to $349.00 and gave the stock a “neutral” rating in a research report on Monday, December 6th. JPMorgan Chase & Co. set a $180.00 target price on shares of BioNTech in a report on Wednesday, November 10th. Finally, Bryan, Garnier & Co set a $359.00 target price on shares of BioNTech in a report on Tuesday, October 5th.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Harbor Investment Advisory LLC purchased a new position in BioNTech during the third quarter valued at approximately $25,000. Creative Financial Designs Inc. ADV purchased a new position in BioNTech during the third quarter valued at approximately $27,000. Activest Wealth Management purchased a new position in BioNTech during the fourth quarter valued at approximately $31,000. Carroll Financial Associates Inc. grew its position in BioNTech by 266.7% during the fourth quarter. Carroll Financial Associates Inc. now owns 165 shares of the company’s stock valued at $42,000 after purchasing an additional 120 shares in the last quarter. Finally, Mark Sheptoff Financial Planning LLC purchased a new position in BioNTech during the second quarter valued at approximately $45,000. 15.12% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech stock opened at $196.00 on Wednesday. The company has a quick ratio of 2.68, a current ratio of 2.76 and a debt-to-equity ratio of 0.03. The firm has a 50-day moving average price of $267.89 and a two-hundred day moving average price of $288.88. The firm has a market capitalization of $47.53 billion, a price-to-earnings ratio of 5.65 and a beta of -1.38. BioNTech has a 52-week low of $90.29 and a 52-week high of $464.00.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, November 8th. The company reported $12.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.54 by $1.81. The firm had revenue of $6.09 billion during the quarter, compared to analyst estimates of $5.02 billion. BioNTech had a net margin of 54.34% and a return on equity of 166.48%. BioNTech’s revenue was up 8918.2% on a year-over-year basis. During the same period in the previous year, the business posted ($1.03) EPS. Research analysts expect that BioNTech will post 39.23 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.

See Also: Hedge Funds – How They Work For Investors

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.